Phase 2 N=124 Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
Tourette Syndrome
Primary: Change From Baseline to Week 8 in the YGTSS TTS — -6.1; -7.4; -8.0 Least Squares Mean (Standard Error) — p=0.4326
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=83 FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma
Primary: Overall Survival (OS) — 9.38; 14.7 Months
Phase 2 N=50 Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women
Tuberculosis
Primary: Clearance Relative to Bioavailability (CL/F) for Rifapentine (RPT) for Intensive and Sparse PK — 1.4; 1.50 L/hr
Phase 2 N=121 Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy
Cat Allergy · Cat Hypersensitivity
Primary: Total Nasal Symptom Score (TNSS) Area Under the Curve (AUC) — 2.46; 2.81; 3.66; 3.10 Total Nasal Symptom Score * Hour — p=0.314
Phase 2 N=23 A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)
Prostate Carcinoma Metastatic to the Bone · Castration Resistant Prostate Cancer
Primary: Percentage of Participants With at Least (>=) 1 Responding Bone Lesion Assessed by Total Sodium Fluoride (NaF) Standardized Uptake Value [SUVtotal] at Third 18F-NaF…
Phase 2 N=122 Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Recurrent Childhood Anaplastic Large Cell Lymphoma · Recurrent Malignant Solid Neoplasm · Recurrent Neuroblastoma
Primary: Maximum-tolerated Dose and Recommended Phase 2 Dose of Crizotinib — 280 mg/m²/dose BID
Phase 2 N=20 Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
Leukemia · Lymphoma
Primary: Treatment-Related Mortality (TRM) — 18 Participants
Phase 2 N=75 High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
Myeloma
Primary: Participants Who Had Measurable Disease at Time of Transplant and Achieved a Stringent Complete Remission — 16 Participants
Phase 2 N=30 Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
HIV · Human Immunodeficiency Virus
Primary: Cell-associated HIV RNA — 1.7; 1.9; 1.6 Fold change
Phase 2 N=100 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Colorectal Cancer · Neoplasms, Colorectal
Primary: Percentage of Participants With Progression-Free Survival at 16 Weeks After Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (5-FU)…
Phase 2 N=22 Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
Epilepsy · SUDEP
Primary: Study Recruitment Rate — 3.8 participants/3 months
Phase 2 N=213 An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute · Myelodysplastic Syndromes
Primary: MDS Cohort: Overall Response Rate — 61.9; 47.6 percentage of participants — p=0.1838
Phase 2 N=100 Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel
Acute Coronary Syndrome · Angina, Unstable
Primary: Number of Participants With a Change in high-on Treatment Platelet Reactivity (HPR) — 37; 33; 24; 0 count of participants
Phase 2 N=14 Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP Study)
Retinopathy of Prematurity
Primary: Efficacy as Measured by the Number of Participants Presenting With Retinopathy of Prematurity (ROP) and the Rate of Stages/Grade of ROP. — 5; 3; 4; 1 Participants
Phase 2 N=12 Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
AIDS-Related-Primary Central Nervous System Lymphoma
Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants